4D Molecular Therapeutics
FDMT
89 hedge funds and large institutions have $182M invested in 4D Molecular Therapeutics in 2022 Q2 according to their latest regulatory filings, with 23 funds opening new positions, 27 increasing their positions, 23 reducing their positions, and 12 closing their positions.
21,600% more call options, than puts
Call options by funds: $1.08M | Put options by funds: $5K
92% more first-time investments, than exits
New positions opened: 23 | Existing positions closed: 12
17% more repeat investments, than reductions
Existing positions increased: 27 | Existing positions reduced: 23
11% more funds holding
Funds holding: 80 → 89 (+9)
0.82% less ownership
Funds ownership: 81.35% → 80.53% (-0.82%)
54% less capital invested
Capital invested by funds: $395M → $182M (-$214M)
100% less funds holding in top 10
Funds holding in top 10: 2 → 0 (-2)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BI
BVF Inc
San Francisco,
California
|
+$13.1M |
| 2 |
DTC
Deep Track Capital
Greenwich,
Connecticut
|
+$6.73M |
| 3 |
ACH
ArrowMark Colorado Holdings
Denver,
Colorado
|
+$2.71M |
| 4 |
Millennium Management
New York
|
+$1.92M |
| 5 |
Renaissance Technologies
New York
|
+$1.85M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
OCA
Octagon Capital Advisors
New York
|
-$9.08M |
| 2 |
ACM
Aquilo Capital Management
San Francisco,
California
|
-$8.69M |
| 3 |
State Street
Boston,
Massachusetts
|
-$8.33M |
| 4 |
Fidelity Investments
Boston,
Massachusetts
|
-$3.8M |
| 5 |
Janus Henderson Group
London,
United Kingdom
|
-$3.21M |
FDMT Hedge Fund Activity: Q2 2022 in Review
89 of the 5,936 institutional investors tracked by Wall St. Rank reported a position in 4D Molecular Therapeutics (FDMT) for Q2 2022, worth a combined $182M — down 54% from $395M a quarter earlier.
Buyers outnumbered sellers: 23 funds opened new FDMT positions and 12 closed out — a net gain of 11 holders — while 27 added to existing stakes and 23 trimmed.
The largest buyer was BVF Inc, adding an estimated $13.1M. The largest seller was Octagon Capital Advisors, cutting an estimated $9.08M.
- 89 institutional investors held 4D Molecular Therapeutics (FDMT) as of Q2 2022, up from 80 in Q1 2022.
- Funds reported $182M of 4D Molecular Therapeutics stock for Q2 2022, down 54% quarter-over-quarter.
- 23 funds opened new 4D Molecular Therapeutics positions in Q2 2022 and 12 closed out, a net change of +11 holders.
- The largest 4D Molecular Therapeutics buyer in Q2 2022 was BVF Inc, an estimated $13.1M added.
- The largest 4D Molecular Therapeutics seller in Q2 2022 was Octagon Capital Advisors, an estimated $9.08M sold.
Based on aggregated 13F filings for Q2 2022.